Tag: congenital heart disease market

Discover trends, market shifts, and competitive outlooks for the congenital heart disease (chd) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Are the Projected Market Size and Growth Rates for the Congenital Heart Disease (CHD) Market From 2025 To 2029?#_x000D_

The market for congenital heart disease (CHD) has seen a significant surge in recent years, escalating from a value of $4.42 billion in 2024 to an anticipated $4.87 billion in 2025, representative of a compound annual growth rate (CAGR) of 10.1%. The upward trend observed in the historic period can be linked to a rise in risk factors including obesity and smoking. Furthermore, the advancement in diagnostic tools, growth in the elderly population, widespread health awareness drives, better reimbursement policies, and enhanced funding for research and development have also contributed to this growth._x000D_

_x000D_

The market size of congenital heart disease (CHD) is predicted to witness robust expansion in the forthcoming years, reaching an estimated value of $7.05 billion in 2029 with a compound annual growth rate (CAGR) of 9.7%. The projected rise during this period is tied to increased availability of healthcare services in developing regions, consistent advancements in cardiac imaging methods, proactive awareness strategies emphasizing early detection and intervention, escalating global healthcare expenditures, and the advancement towards individualized medicine. Noteworthy trends during this forecast period encompass the utilization of minimally invasive surgical approaches, the growing application of telemedicine for remote patient surveillance and consultation, escalating requirements for tailor-made treatment methodologies, the creation of novel implantable apparatus with better performance and lifespan, and the incorporation of artificial intelligence and machine learning into diagnostic and therapeutic procedures._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp_x000D_

_x000D_

#Which Major Market Drivers Are Expected to Boost the Growth Potential of the Congenital Heart Disease (CHD) Market?#_x000D_

The anticipated surge in cases of maternal diabetes is projected to boost the congenital heart disease (CHD) market in the coming years. Maternal diabetes, or gestational diabetes mellitus (GDM), is a form of diabetes that develops in women during pregnancy, who previously did not have the condition. The onset of maternal diabetes is triggered by changes in lifestyle patterns such as sedentary behavior and unhealthy eating habits, as well as a general increase in obesity rates among women of reproductive age. Maternal diabetes can trigger CHD in infants due to the impact of high blood sugar levels on fetal heart development. The high glucose levels in the mother’s blood can interfere with the normal development of the baby’s heart, thus enhancing the risk of CHD. For instance, the National Health Service, a UK-based government department, reported in October 2023 that negative pregnancy outcomes for women diagnosed with type 2 diabetes increased from 4.9% in 2021 to 6.6% in 2022. Consequently, the escalating cases of maternal diabetes are fueling CHD market growth._x000D_

_x000D_

#Which Key Market Segments Comprise the Congenital Heart Disease (CHD) Market and Drive Its Revenue Growth?#_x000D_

The congenital heart disease (CHD) market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types_x000D_

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis_x000D_

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications_x000D_

4) By Age Group: Infants, Children, Adolescents, Adults_x000D_

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions_x000D_

_x000D_

Subsegments:_x000D_

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation_x000D_

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)_x000D_

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus_x000D_

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction_x000D_

_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Congenital Heart Disease (CHD) Market Expansion Across the Globe?#_x000D_

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Key Market Trends in theCongenital Heart Disease (CHD) Market Over the Coming Years?#_x000D_

Leading firms in the congenital heart disease market are focusing on the creation of non-surgical heart valves to enhance patient outcomes and quality of life. Such heart valves, also known as transcatheter, are medical aids designed to address heart valve ailments without the need for traditional open-heart surgery. In a notable example from February 2023, Medtronic, an American medical technology firm, relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System. This system, a revolutionary minimally invasive alternative to open-heart surgery, caters to patients with congenital heart disease specifically those who have native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It’s first of its kind valve system approved by FDA and designed for the right side of heart. It is intended to offer a non-surgical remedy for patients dealing with severe pulmonary valve regurgitation. The much talked about Harmony TPV System got its nod from the U.S. FDA in 2021, and was later relaunched post a voluntary recall. This move signifies Medtronic’s dedication towards developing impactful solutions for congenital heart disease patients._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report_x000D_

_x000D_

#How Is the Congenital Heart Disease (CHD) Market Conceptually Defined?#_x000D_

Congenital heart disease (CHD) refers to a range of birth defects affecting the structure and function of the heart that are present at birth. These defects can involve the walls of the heart, the valves of the heart, and the arteries and veins near the heart. The treatment for CHD depends on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Congenital Heart Disease (CHD) Market?

The rise of maternal diabetes occurrences is anticipated to fuel the congenital heart disease (CHD) market’s expansion. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a type of diabetes that develops in women who were not previously diagnosed with the condition prior to their pregnancy. This form of diabetes is triggered by lifestyle modifications, such as a lack of physical activity and unhealthy food choices, as well as a general upsurge in obesity among women within the childbearing age range. An increase in maternal diabetes can result in congenital heart disease (CHD) in newborns, with high blood glucose levels interfering with fetal heart development. Excess glucose in the mother’s bloodstream can hinder the standard development process of the child’s heart, raising the chances of CHD. For instance, the National Health Service, a government department in the UK, reported in October 2023 that there was a rise from 4.9% in 2021 to 6.6% in 2022 in adverse pregnancy outcomes for women diagnosed with type 2 diabetes. As a result, the surge in maternal diabetes occurrences is contributing to the growth of the congenital heart disease (CHD) market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

What is the Predicted Annual Growth Rate of theCongenital Heart Disease (CHD) Market Impact Industry Trends by 2034?

The market size for congenital heart disease (CHD) has seen considerable growth in the last few years. It’s predicted to increase from $4.42 billion in 2024 to $4.87 billion in 2025 with a compound annual growth rate (CAGR) of 10.1%. The previous upward trend can be linked to the rising occurrence of risk elements like obesity and smoking, advancements in diagnostic technologies, an enlarging elderly population, more effective awareness campaigns, improved reimbursement strategies, and a heightened financial commitment to research and development.

The market for congenital heart disease (CHD) is projected to experience significant expansion in the coming years, escalating to a value of $7.05 billion by 2029 with a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth within the forecast period include broader access to healthcare in developing areas, ongoing advancements in cardiac imaging technologies, increased awareness initiatives focusing on early diagnosis and management, escalating worldwide healthcare spending, and the evolution of personalized medicine. Key trends influencing this period reveal a shift towards minimally invasive surgical methods, growing application of telemedicine for remote patient consultation and observation, a surge in the pursuit of personalized treatment strategies, the creation of innovative implantable devices having improved performance and lifespan, along with the introduction of artificial intelligence and machine learning into diagnostic and medicinal procedures.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545

What Are the Key Market Innovations in theCongenital Heart Disease (CHD) Market Over the Coming Years?

Key players in the congenital heart disease market are innovating non-surgical heart valves to enhance patient health and lifestyle. Transcatheter heart valves, an alternative to traditional open-heart surgery, are medical instruments used to cure heart valve diseases. For example, Medtronic, an American medical technology firm, re-launched its Harmony Transcatheter Pulmonary Valve (TPV) System in February 2023. It offers a revolutionary, minimally invasive substitute to open-heart surgery for individuals with congenital heart disease, specifically those dealing with native or surgically corrected right ventricular outflow tract (RVOT) abnormalities. This is the first FDA-approved valve exclusively for the right side, giving a non-surgical route for patients experiencing severe pulmonary valve regurgitation. The Harmony TPV System got the green light from the U.S. FDA back in 2021 and was reissued after a voluntary recall. This reflects Medtronic’s promise to driving innovation for patients affected by congenital heart disease.

Who Are the Top Companies Driving Innovation and Growth in theCongenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Key Market Segments Comprise the Congenital Heart Disease (CHD) Market and Drive Its Revenue Growth?

The congenital heart disease (CHD) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Which Regions Are Emerging as Leaders in the Congenital Heart Disease (CHD) Market?

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2025, By The Business Research Company:

Cardiovascular Digital Solutions Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-digital-solutions-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiovascular Ultrasound Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the congenital heart disease (chd) market right now?

The congenital heart disease (CHD) market has grown rapidly in recent years. It is set to increase from $4.42 billion in 2024 to $4.87 billion in 2025, at a compound annual growth rate (CAGR) of 10.1%. The market’s expansion is attributed to factors such as higher prevalence of risk factors like obesity and smoking, better diagnostic technologies, an aging population, heightened awareness campaigns, improved reimbursement policies, and more investment in research and development.

How fast Is the congenital heart disease (chd) market expected to grow, and what’s its future value?

The congenital heart disease (CHD) market is projected to reach $7.05 billion by 2029, growing at a CAGR of 9.7%. Growth is driven by expanded healthcare access in developing regions, innovations in cardiac imaging, awareness campaigns for early detection, rising healthcare expenditures, and the development of personalized medicine. Key trends include minimally invasive surgery, telemedicine for remote monitoring, personalized treatments, innovative implantable devices, and AI/machine learning in diagnostics.

Get your congenital heart disease (chd) market report here!

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

What are the leading drivers of growth in the congenital heart disease (chd) market?

The increase in maternal diabetes cases is expected to drive growth in the congenital heart disease (CHD) market. Maternal diabetes, which can lead to congenital heart defects in infants, is on the rise due to factors like sedentary lifestyles and unhealthy eating habits. The National Health Service in October 2023 reported that adverse pregnancy outcomes in women with type 2 diabetes increased from 4.9% in 2021 to 6.6% in 2022. This rise in maternal diabetes cases is fueling the growth of the CHD market.

What are the key segments defining the congenital heart disease (chd) market?

The congenital heart disease (CHD) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

Who are the key players steering the development of the congenital heart disease (chd) market?

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

What emerging trends are influencing the growth of the congenital heart disease (chd) market?

Companies in the congenital heart disease market are focusing on non-surgical heart valves to provide minimally invasive treatment options. Non-surgical valves offer an alternative to open-heart surgery, improving patient outcomes. For example, in February 2023, Medtronic, a US-based medical technology company, reintroduced the Harmony Transcatheter Pulmonary Valve (TPV) System. This FDA-approved valve provides a non-surgical solution for patients with severe pulmonary valve regurgitation, advancing treatment options for congenital heart disease.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545

Which regions are most influential in expanding the congenital heart disease (chd) market?

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Digital Solutions Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-digital-solutions-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiovascular Ultrasound Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted CAGR for the Congenital Heart Disease (CHD) Market Over the Forecast Period of 2025 to 2034?

In recent times, there has been a swift expansion in the congenital heart disease (CHD) market. It is projected to inflate from $4.42 billion in 2024 to about $4.87 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The surge during the historic period is influenced by several factors including the rising incidences of risk factors such as obesity and smoking, advancements in diagnostic technology, growing elderly population, amplified awareness campaigns, improved reimbursement procedures, as well as amplified funding in research and development.

Anticipated to witness significant growth in the near future, the market size of congenital heart disease (CHD) is predicted to escalate to $7.05 billion by the year 2029, maintaining a compound annual growth rate (CAGR) of 9.7%. This rising trend during the forecasted period is ascribed to the increasing availability of healthcare amenities in the emerging regions, ongoing advancements in cardiac imaging technology, enhanced emphasis on early detection and solution via awareness campaigns, heightened global healthcare spending, and the evolution of individualized medicine. Dominant patterns during this period involve the incorporation of minimally invasive surgical procedures, extended use of telemedicine for distant patient monitoring and consultations, growing requirement for tailored treatment methods, the production of pioneering implantable apparatus featuring improved performance and durability, along with the integration of artificial intelligence and machine learning into diagnostic and therapeutic procedures.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Congenital Heart Disease (CHD) Market?

The surge in instances of maternal diabetes is predicted to spur the growth of the congenital heart disease (CHD) market in the future. Maternal diabetes, known as gestational diabetes mellitus (GDM), is defined as the emergence of diabetes in females during pregnancy who were not previously diabetic. The reasons for maternal diabetes are modifications in lifestyle such as lack of physical activity, unhealthy eating patterns, and the overall increase in obesity amongst reproductive-age women. Maternal diabetes can predispose infants to congenital heart disease (CHD) due to high blood sugar levels impacting the heart’s development during fetal stages. This elevated glucose level in a pregnant woman’s blood can adversely affect the normal growth of an infant’s heart, leading to a higher probability of CHD. For example, the National Health Service, a government department in the UK, reported in October 2023 that the adverse pregnancy outcomes increased from 4.9% in 2021 to 6.6% in 2022 amongst women diagnosed with type 2 diabetes. Consequently, the surge in maternal diabetes cases is fuelling the growth of the congenital heart disease (CHD) market.

Request Your Free Congenital Heart Disease (CHD) Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

Who Are the Top Companies Driving Innovation and Growth in the Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (CHD) market are:

• Pfizer Inc.

• AstraZeneca Plc

• Abbott Laboratories

• Novartis AG

• Medtronic

What Key Trends Are Currently Impacting the Congenital Heart Disease (CHD) Market’s Development?

Key players in the congenital heart disease marketplace are advancing towards the creation of non-surgical heart valves with the aim of enhancing both patient outcomes and life quality. These non-surgical or transcatheter heart valves are healthcare apparatuses that serve to manage heart valve illnesses without the necessity for conventional open-heart operations. For instance, in February 2023, Medtronic, an American medical tech firm, relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System. This innovative, minimally invasive option provides an alternative to open-heart surgery for congenital heart disease patients, particularly those with inherent or surgically corrected right ventricular outflow tract (RVOT) irregularities. The System, which is the first FDA-approved valve specifically designed for the right side, offers a non-surgical remedy for severe pulmonary valve regurgitation patients. In 2021, the Harmony TPV System acquired approval from the U.S FDA. Its reintroduction after a voluntary recall is demonstrative of Medtronic’s dedication to progressing solutions for those suffering from congenital heart disease.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Key Segments Define the Structure of the Congenital Heart Disease (CHD) Market and Their Growth Potential?

The congenital heart disease (CHD) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Which Geographical Regions Are Pioneering Growth in the Congenital Heart Disease (CHD) Market?

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Aspects of the Congenital Heart Disease (CHD) Market Landscape?

Congenital heart disease (CHD) refers to a range of birth defects affecting the structure and function of the heart that are present at birth. These defects can involve the walls of the heart, the valves of the heart, and the arteries and veins near the heart. The treatment for CHD depends on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation.

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Digital Solutions Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-digital-solutions-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiovascular Ultrasound Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: